In last trading session, Cns Pharmaceuticals Inc (NASDAQ:CNSP) saw 0.67 million shares changing hands with its beta currently measuring 1.06. Company’s recent per share price level of $3.23 trading at -$0.52 or -13.87% at ring of the bell on the day assigns it a market valuation of $3.71M. That closing price of CNSP’s stock is at a discount of -36896.9% from its 52-week high price of $1195.00 and is indicating a discount of -2.17% from its 52-week low price of $3.30.
Cns Pharmaceuticals Inc (NASDAQ:CNSP) trade information
Upright in the red during last session for losing -13.87%, in the last five days CNSP remained trading in the red while hitting it’s week-highest on Friday, 02/14/25 when the stock touched $3.23 price level, adding 66.0% to its value on the day. Cns Pharmaceuticals Inc’s shares saw a change of -46.35% in year-to-date performance and have moved -40.07% in past 5-day. Cns Pharmaceuticals Inc (NASDAQ:CNSP) showed a performance of -37.28% in past 30-days.
Wall Street analysts have assigned a consensus price target of 0.5 to the stock, which implies a fall of -546.0% to its current value. Analysts have been projecting 0.5 as a low price target for the stock while placing it at a high target of 0.5. It follows that stock’s current price would jump 84.52% in reaching the projected high whereas dropping to the targeted low would mean a gain of 84.52% for stock’s current value.
Cns Pharmaceuticals Inc (CNSP) estimates and forecasts
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 17.98% during past 5 years.
On the other hand, Fidelity Extended Market Index Fund and Fidelity Series Total Market Index Fund are the top two Mutual Funds which own company’s shares. As of Nov 30, 2024 , the former fund manager was holding 161.12 shares of worth $0.52 million or 0.21% of the total outstanding shares. The later fund manager was in possession of 37.94 shares on Nov 30, 2024 , making its stake of worth around $0.12 million in the company or a holder of 0.05% of company’s stock.
